Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Azd-9833
2. Azd9833
3. N-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo(4,3-f)isoquinolin-6-yl)pyridin-3-amine
1. Azd-9833
2. Unii-jup57a8epz
3. Azd9833
4. 2222844-89-3
5. Camizestrant [usan]
6. Jup57a8epz
7. Az14066724
8. Az-14066724
9. N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine
10. 3-pyridinamine, N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-6,7,8,9-tetrahydro-8-methyl-7-(2,2,2-trifluoroethyl)-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-
11. Camizestrant [inn]
12. Camizestrant [who-dd]
13. Chembl4650365
14. Schembl20089710
15. Ex-a5025
16. Nsc828717
17. Who 11592
18. At22885
19. Nsc-828717
20. Hy-136255
21. Cs-0121043
22. N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamine
23. N-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine
| Molecular Weight | 476.5 g/mol |
|---|---|
| Molecular Formula | C24H28F4N6 |
| XLogP3 | 4.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 7 |
| Exact Mass | 476.23115757 g/mol |
| Monoisotopic Mass | 476.23115757 g/mol |
| Topological Polar Surface Area | 60.1 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 674 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
NDC API
NDC Package Code : 59116-7280
Start Marketing Date : 2023-06-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Camizestrant (AZD9833) is a potent, next-generation oral SERD and pure ERα antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations.
Lead Product(s): Camizestrant,Palbociclib,Luteinizing Hormone
Therapeutic Area: Oncology Brand Name: AZD9833
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Lead Product(s) : Camizestrant,Palbociclib,Luteinizing Hormone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Camizestrant (AZD9833) is a potent, next-generation oral SERD and pure ERα antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations.
Brand Name : AZD9833
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 08, 2022
Details:
AZD9833 (camizestrant) is a potent, next-generation oral SERD and pure ERα antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations.
Lead Product(s): Camizestrant
Therapeutic Area: Oncology Brand Name: AZD9833
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Lead Product(s) : Camizestrant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERE...
Details : AZD9833 (camizestrant) is a potent, next-generation oral SERD and pure ERα antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations.
Brand Name : AZD9833
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 26, 2022
Details:
New data from the SERENA-1 Phase I trial show strong efficacy and safety profile for next-generation oral SERD AZD9833 in HR-positive advanced breast cancer.
Lead Product(s): Camizestrant,Palbociclib
Therapeutic Area: Oncology Brand Name: AZD9833
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Lead Product(s) : Camizestrant,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : New data from the SERENA-1 Phase I trial show strong efficacy and safety profile for next-generation oral SERD AZD9833 in HR-positive advanced breast cancer.
Brand Name : AZD9833
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Camizestrant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Camizestrant, including repackagers and relabelers. The FDA regulates Camizestrant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Camizestrant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Camizestrant supplier is an individual or a company that provides Camizestrant active pharmaceutical ingredient (API) or Camizestrant finished formulations upon request. The Camizestrant suppliers may include Camizestrant API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Camizestrant as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Camizestrant API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Camizestrant as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Camizestrant and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Camizestrant NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Camizestrant suppliers with NDC on PharmaCompass.
Camizestrant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Camizestrant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Camizestrant GMP manufacturer or Camizestrant GMP API supplier for your needs.
A Camizestrant CoA (Certificate of Analysis) is a formal document that attests to Camizestrant's compliance with Camizestrant specifications and serves as a tool for batch-level quality control.
Camizestrant CoA mostly includes findings from lab analyses of a specific batch. For each Camizestrant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Camizestrant may be tested according to a variety of international standards, such as European Pharmacopoeia (Camizestrant EP), Camizestrant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Camizestrant USP).
LOOKING FOR A SUPPLIER?
